Quick Answer
Cocrystal Pharma, Inc. reported Revenue (ASC 606) of $2.01 million for fiscal year 2020.
Cocrystal Pharma, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2020 | $2.01M | -69.3% |
| 2019 | $6.56M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2020 | $489.0K | -0.6% | -11.7% |
| June 30, 2020 | $554.0K | -6.4% | +20.2% |
| March 31, 2020 | $461.0K | -90.9% | -6.3% |
| September 30, 2019 | $492.0K | — | -16.9% |
| June 30, 2019 | $592.0K | — | -88.3% |
| March 31, 2019 | $5.08M | — | — |
- Cocrystal Pharma, Inc. showed a decrease of -69.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2019–2020 period, Cocrystal Pharma, Inc.’s revenue (asc 606) has declined by 69.3% (from $6.56 million to $2.01 million).
- The most recent figure is from Cocrystal Pharma, Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on March 23, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: